Open Calculator Browse Protocols → Shop Compounds →
peppercalc.com · research use only
Peptide Protocol

ARA-290: innate repair receptor agonist — nerve and tissue healing.

Non-hematopoietic EPO analog targeting the innate repair receptor. Neuroprotective, anti-inflammatory, and metabolic. SubQ.

Open Calculator All Protocols →
peppercalc.com · research use only
Home› Protocols› ARA-290
Repair Peptide Research Use Only

ARA-290
Dosage Protocol

ARA-290 is a synthetic 11-amino acid peptide designed to activate the innate repair receptor (IRR) — a heterodimer of erythropoietin receptor (EPOR) and the common beta receptor (CD131). Unlike erythropoietin itself, ARA-290 does not stimulate red blood cell production but instead specifically activates tissue-protective and repair pathways in neurons, immune cells, and metabolic tissue.

4–8 mg
Per Dose
4–12 weeks
Cycle
SubQ
Route
3× weekly
Frequency
Overview

What is ARA-290?

ARA-290 was engineered by the Gordijn/Brines group at Yale University to specifically target the innate repair receptor (EPOR/CD131 heterodimer) while avoiding the erythropoiesis-stimulating homodimeric EPOR. This selectivity allows activation of tissue-protective EPO signaling without erythrocytic effects — eliminating the thrombosis and polycythemia risks of therapeutic EPO.

Clinical trials have demonstrated ARA-290's efficacy in painful diabetic neuropathy and sarcoidosis-associated small-fiber neuropathy — with significant improvements in nerve fiber density, pain scores, and autonomic function. It also shows promise for metabolic effects including improved insulin sensitivity and reduced inflammatory markers.

Innate Repair Receptor
Selectively activates the EPOR/CD131 heterodimer on non-hematopoietic cells — triggering tissue-protective JAK2/STAT5 and PI3K/AKT signaling.
Nerve Fiber Regeneration
Clinical data shows increased intraepidermal nerve fiber density in diabetic neuropathy — direct evidence of peripheral nerve regeneration.
Anti-Inflammatory
Reduces macrophage-mediated inflammation and inflammatory cytokine production in multiple tissue types through IRR-mediated pathways.
Metabolic Improvement
Improves pancreatic beta-cell survival and insulin sensitivity through IRR activation in metabolic tissues — independent of erythropoietic effects.
Dosing Protocol

Dosing Schedule

Parameters documented in published preclinical and clinical research.

Research use only. The following documents parameters from published preclinical and clinical research. Not medical advice. Not for human consumption. Consult a licensed healthcare professional before any use.
PhaseDoseFrequencyDurationNotes
Clinical4 mg3× weekly SubQ4–12 weeksDose and schedule from published sarcoidosis and neuropathy trials.
Working dose4–8 mg3× weekly8–12 weeksSubQ abdomen or thigh. Clinical trials used 4 mg 3× weekly most commonly.
Maintenance4 mg2× weeklyOngoingLower-frequency maintenance after initial treatment course.
Off cycle——4–8 weeksCycle off and reassess nerve and pain outcomes.
Safety Profile

Safety & Side Effects

Generally Well Tolerated
Phase 2 clinical trial data in diabetic and sarcoidosis neuropathy
No erythropoiesis — no thrombosis or polycythemia risk
Documented peripheral nerve fiber regeneration in humans
Excellent tolerability in published clinical trials
Potential Concerns
Not FDA-approved — research compound status
Limited long-term safety data beyond 12-week trials
Subcutaneous administration required — no oral formulation
Production and quality control variable in research suppliers
Research use onlyThis page is an educational reference. None of this constitutes medical advice. Consult a qualified professional before any use. All compounds are for research purposes only.
Evidence Base

Academic References

  1. [1]
    Brines M, et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA. 105(31):10925–30. PubMed ↗
  2. [2]
    Dahan A, et al. (2013). ARA 290, a synthetic erythropoietin mimetic, reduces pain in patients with fibromyalgia. Pain. 154(9):1526–33. PubMed ↗
  3. [3]
    Culver DA, et al. (2017). Pilot study of ARA 290, an erythropoietin analog, in sarcoidosis-associated small-fiber neuropathy. Sarcoidosis Vasc Diffuse Lung Dis. 34(2):103–13. PubMed ↗
  4. [4]
    Heij L, et al. (2015). ARA290 treatment improves symptoms in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 32(3):237–45. PubMed ↗
Recommended Source
Source your compounds at White Market Peptides
Use code PEPPERCALC10 for 10% off + free 2-day shipping over $200
Shop Now →